Interferon gamma in the treatment of patients with moderate COVID-19 | Zendy

Alexandr Myasnikov | Zendy; С. А. Бернс | Zendy; P. A. Talyzin | Zendy; Ershov Fi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interferon gamma in the treatment of patients with moderate COVID-19

Author(s) -

Alexandr Myasnikov,

С. А. Бернс,

P. A. Talyzin,

Ershov Fi

Publication year - 2021

Publication title -

problems of virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.151

H-Index - 15

eISSN - 2411-2097

pISSN - 0507-4088

DOI - 10.36233/0507-4088-24

Subject(s) - medicine , pneumonia , intensive care unit , viral pneumonia , interferon , immune system , interferon gamma , immunology , coronavirus , vital signs , covid-19 , intensive care medicine , disease , surgery , infectious disease (medical specialty)

Interferons are produced in response to the presence of pathogens in cells and are responsible for the proper formation of immune reaction. Preliminary data obtained in studies of properties of recombinant interferon gamma (IFN-γ) that involved patients with community-acquired pneumonia (including bacterial), acute respiratory viral infection (ARVI), influenza and new coronavirus infection have shown promising results.The purpose of the study was to assess the effect of subcutaneous administration of IFN-γ in patients with viral pneumonia on the changes of vital signs and the duration of hospital stay.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research